- Home
- TFFP vs FBRX Comparison
TFFP vs FBRX Comparison
Compare TFFP & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TFFP
- FBRX
- Stock Information
- Founded
- TFFP 2018
- FBRX N/A
- Country
- TFFP United States
- FBRX United States
- Employees
- TFFP N/A
- FBRX N/A
- Industry
- TFFP Biotechnology: Pharmaceutical Preparations
- FBRX Biotechnology: Pharmaceutical Preparations
- Sector
- TFFP Health Care
- FBRX Health Care
- Exchange
- TFFP Nasdaq
- FBRX Nasdaq
- Market Cap
- TFFP 6.9M
- FBRX 8.3M
- IPO Year
- TFFP 2019
- FBRX N/A
- Fundamental
- Price
- TFFP $0.39
- FBRX $5.55
- Analyst Decision
- TFFP Strong Buy
- FBRX Strong Buy
- Analyst Count
- TFFP 1
- FBRX 3
- Target Price
- TFFP $44.00
- FBRX $77.58
- AVG Volume (30 Days)
- TFFP 682.5K
- FBRX 13.6K
- Earning Date
- TFFP 11-26-2024
- FBRX 11-14-2024
- Dividend Yield
- TFFP N/A
- FBRX N/A
- EPS Growth
- TFFP N/A
- FBRX N/A
- EPS
- TFFP N/A
- FBRX N/A
- Revenue
- TFFP $1,202,586.00
- FBRX N/A
- Revenue This Year
- TFFP $60.25
- FBRX N/A
- Revenue Next Year
- TFFP N/A
- FBRX N/A
- P/E Ratio
- TFFP N/A
- FBRX N/A
- Revenue Growth
- TFFP 53.17
- FBRX N/A
- 52 Week Low
- TFFP $0.27
- FBRX $4.11
- 52 Week High
- TFFP $11.00
- FBRX $21.25
- Technical
- Relative Strength Index (RSI)
- TFFP 23.82
- FBRX 58.76
- Support Level
- TFFP $1.55
- FBRX $4.44
- Resistance Level
- TFFP $3.23
- FBRX $5.90
- Average True Range (ATR)
- TFFP 0.31
- FBRX 0.37
- MACD
- TFFP -0.12
- FBRX 0.20
- Stochastic Oscillator
- TFFP 0.95
- FBRX 80.45
About TFFP TFF Pharmaceuticals Inc.
TFF Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing drug products based on its patented Thin Film Freezing, or TFF, technology platform. It is focused on the development of inhaled dry powder drugs for the treatment of lung disorders.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA).